EBR Systems Reports Q2 2026 Progress
Key points
- EBR surpassed 100 commercial WiSE implants
- Secured purchasing agreements with major U.S. healthcare networks
- CMS initiated National Coverage Determination process for WiSE
- Transitioned to new manufacturing facility
- Completed $A150M capital raise
Full summary
EBR Systems, Inc. released its Q2 2026 Quarterly Activity Report, highlighting significant progress in commercialization, funding, and reimbursement for its WiSE CRT System. The company surpassed its 100th commercial WiSE implant, with multiple sites performing their first implants. EBR secured purchasing agreements with major U.S. healthcare networks, including HCA Healthcare, Advocate Health, and CHRISTUS Health. The U.S. Centers for Medicare & Medicaid Services (CMS) initiated the National Coverage Determination process for WiSE, a key step toward broader Medicare coverage. EBR also transitioned to its new manufacturing facility in Santa Clara, California, and completed the first two tranches of a $A150 million capital raise. The company ended Q2 2026 with cash, cash equivalents, restricted cash, and marketable securities totaling US$89.5 million.
Guidance
EBR expects to complete the final $A35 million tranche of its capital raise by 24 August 2026.
Outlook
EBR Systems anticipates continued momentum in its commercial efforts, with a positive outcome from the CMS National Coverage Determination process expected in March 2027.
Summary generated by a large language model. Please interpret with care.